InvestorsHub Logo
icon url

TechandBio

08/22/22 8:06 AM

#1439 RE: crudeoil24 #1438

Oncternal therapeutics: Zilovertamab Phase 3 study Ror1 ZILO-301 Kills cancer stem cells. HUGE Improvement Partnered with AbbV better approach then trillium which was bought out by Pfizer for 2.2 Billion for Hematological malignancies cancers. Next we had the 2 ROR1 buyouts last year and half. This stock is about to quantum leap. Under the radar hidden gem. Billion dollar plus market cap in the making. Onct is helping Imbruvica (PCYC) which as bought out by ABBV 21 Billion and has 9 Billion plus in sales. Zilovertamab in combo with Imbruvica is 50% more affective then Imbruvica alone with less side effects. Plus 9 indications in the ONCT pipeline including Prostate & Breast cancer Her2 (39 Billion market for Her2 Breast cancer in 2025 Onct market cap at 65 Million is extremely undervalued. The chart is turning around. Ror1 first in class in the making.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc


This is the most undervalued asset, 'explosive' move coming.



081 - Oncternal Therapeutics Drives Complete Responders with First in Class ROR1 Antagonist



ONCT Team Includes Veterans from Fate therapeutics, Merck, Pfizer, Gilead, Amgen, Johnson & Johnson, Roche, Lilly, & Takeda. Plus the legendary Kipps who was the primary lead investigator for PCYC Imbruvica for 18 years. who were now headed into a phase 3


https://www.fiercebiotech.com/biotech/abbvie-pens-imbruvica-supply-pact-support-pivotal-oncternal-trial


August 2022 ONCT Biz presentation.

https://investor.oncternal.com/static-files/f7628e1c-42c5-4c8a-8247-e910ad5555c4

ONCT Pipeline.

https://www.oncternal.com/pipeline

About 50 million shares outstanding.
% Held by Institutions 31%
% Held by Insiders 11%

Insiders have been buying over the last few months

$ONCT